Lotronex Review May Include Discussion Of Withdrawal Study, Patient Survey

A randomized withdrawal study of GlaxoSmithKline's Lotronex would provide valuable information on the efficacy profile of the irritable bowel syndrome agent, FDA Office of Medical Policy Director Robert Temple, MD, suggested during the Food & Drug Law Institute's educational conference April 16 in Washington, D.C